Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Etf Preview: Broad Market Etfs Mixed As Investors Await Yellen Testimony - Nasdaq.com

ETF Preview: ETFs, Futures Weaker as Second Day of great site Yellen Testimony Begins; January New Home Sales Still Ahead - NASDAQ.com

If, at any time, you are interested in reverting to our default settings, please select Default Setting above. If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com . Please confirm your selection: You have selected to change your default setting for the Quote Search. This will now be your default target page; unless you change your configuration again, or you delete your cookies. Are you sure you want to change your settings?
Source: http://www.nasdaq.com/article/etf-preview-broad-market-etfs-mixed-as-investors-await-yellen-testimony-cm447191

The Street view is for EPS of $1.70 on revenue of $1.48 billion. Energy Dow Jones U.S. Energy Fund (IYE) was flat while Energy Select Sector SPDR (XLE) was up 0.15%. Chesapeake Energy (CHK) was down 4.53% after the U.S. oil and gas company posted mixed Q4 results and announced a 37% cut in capital expenditure for 2015. Adjusted net income was $34 million, or $0.11 per fully diluted share, which compares to adjusted net income available to common stockholders of $161 million, or $0.27 per fully diluted share, in the 2013 fourth quarter.
Source: http://www.nasdaq.com/article/etf-preview-etfs-futures-weaker-as-second-day-of-yellen-testimony-begins-january-new-home-sales-still-ahead-cm448247

ETF Preview: ETFs, Futures Lower Ahead of Existing Homes Sales Data; Investors Await Yellen Testimony - NASDAQ.com

economy continued its above-trend growth. The index had a reading of positive 0.13 during the month, up from negative 0.07 in December. Still ahead, existing-home sales for January will be released at 10 am ET. Rigel Pharmaceuticals (RIGL) was up 45% after announcing it is collaborating with Bristol-Myers Squibb (BMY) on discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. Bristol Myers-Squibb will pay $30 million upfront and Rigel is eligible to receive development and regulatory milestones that could total more than $309 million for a successful compound approved in multiple indications.
Source: http://www.nasdaq.com/article/etf-preview-etfs-futures-lower-ahead-of-existing-homes-sales-data-investors-await-yellen-testimony-cm446965

Tuttle Tactical Management to Launch Inaugural ETF - Yahoo Finance

TUTT is an ETF which seeks long-term capital appreciation while maintaining a secondary emphasis on capital preservation, primarily through investments in the U.S. equity market. The Fund is an ETF of ETFs that seeks to provide attractive returns during market upturns while maintaining the ability to protect capital during market downturns by employing a multi-strategy, tactically-managed exposure to U.S. equity markets. The tactical nature of the Funds objective is a pre-determined strategy which, while active, reacts to market indicators rather than attempts to use them as predictors of market direction.
Source: http://finance.yahoo.com/news/tuttle-tactical-management-launch-inaugural-143300516.html

Don't be the product, buy the product!